Strength & Performance
Research compounds for lean mass, recovery, and momentum at any stage — in plain language.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
BPC-157 is one of the most-discussed compounds in the recovery and repair conversation right now. You will hear it called a healing peptide, a tendon-repair compound, a recovery aid. Behind the labels is a body of research that is mostly one specific kind — preclinical. Here is what the review shows, in plain English.
Thymosin Beta-4 and Cardiac Repair After Reperfusion
Thymosin beta-4 is studied for cardiac repair after ischemic injury. A 2025 paper pairs a mouse ischemia model with a small STEMI patient cohort. Here is what the research shows — no jargon, no hype, and where the evidence stops.
GHRH Analog and the Hormone Axis in Age-Advanced Adults
If you have ever looked into growth hormone, IGF-1, recovery, or strength, you have been looking at the downstream stuff. Sermorelin sits upstream of all of it. Here is what one 1997 study actually showed — no jargon, no hype.
The Repair Finding: BPC-157 and Tendon-to-Bone Healing
In preclinical models, BPC-157 was associated with accelerated tendon-to-bone healing and ligament repair. Here is what was actually reported — and what that does and does not tell you.
The Mouse Model: Cardiac Function After Reperfusion
In a mouse ischemia model, thymosin beta-4 was associated with improved cardiac function after reperfusion. Here is what was actually measured — and what a mouse model can and cannot tell you.
The IGF-1 Shift: What the Marker Actually Did
The headline result from the 1997 study is that IGF-1 — the downstream marker of growth-hormone signaling — shifted in the studied direction in age-advanced adults. Here is what was measured, in plain English.
New Blood Vessels at the Healing Site: The Angiogenesis Finding
Reported effects included improved angiogenesis — new blood vessel formation — at healing sites in the studied models. Here is what that means and what it does and does not tell you.
The STEMI Cohort: Remodeling Signals in Patients
In a small cohort of STEMI patients, thymosin beta-4 showed signals of improved cardiac remodeling after reperfusion. Here is what a signal in a small cohort does and does not mean.
Upstream, Not Replacement: Why the Pulse Matters
The GHRH analog worked at the pituitary layer, preserving the body's own pulsatile growth-hormone pattern rather than replacing the hormone directly. Here is why that distinction matters.
Mostly Preclinical: What the Evidence Base Actually Is
Most of the BPC-157 evidence is from animal and lab models; controlled human trials are limited. Here is exactly what that means and why it matters more than any single finding.
Why This Is Early-Stage Evidence, Not a Proven Therapy
The 2025 paper is an animal model plus a small human cohort, not a large controlled trial. Here is what that evidence base can and cannot support — and why the difference matters.
The Body-Composition Shift: Modest, Not Magic
Body-composition markers shifted modestly in the studied group over the administration window. Here is exactly what that does and does not tell you.
Long History, Thin Database: The Safety Story
The compound has a long history of described use but a thin formal safety database in humans. Here is exactly how that is — and is not — a safety claim.
Small Study, Limited Window: The Honest Edges
The study was small and the window was limited; long-term outcomes in broader populations were not established. Here is exactly how to read that — and how not to.
Have a question about your work?
Talk it through with a research specialist — private, written, no commitment.